Analysis on Financial Conditions of Listed Pharmaceutical Manufacturing Companies Based on F-score Model in the Context of COVID-19

A Case Study of SHIYAO Pharmaceutical Group in China

DOI

10.2991/aebmr.k.220405.087How to use a DOI?

Keywords

COVID-19; pharmaceutical manufacturing industry; financial condition; F-score model

Abstract

Against the background of the sudden outbreak of COVID-19, it has also been accompanied by a number of policy changes related to medicine. Pharmaceutical manufacturing industry is characterized by high investment, high risk and high income, so it is quite necessary for the listed pharmaceutical manufacturing industry to prevent financial risk and improve management level from both internal and external aspects [1]. In this paper, the F-score model is used to analyze the financial data of SHIYAO Group from 2017 to 2021, and obtain which ones are in good financial condition and which ones have bankruptcy risk, as well as the comparison of different kinds of drugs. Through the dynamic change process, this study analyzes the specific situation of different types of drugs, summarizes the adjustment experience of enterprises, draws lessons and seek innovation channels. In total, according to the research results, the financial condition was affected but still in good state.

Copyright

© 2022 The Authors. Published by Atlantis Press International B.V.

Open Access

This is an open access article distributed under the CC BY-NC 4.0 license.

Download article (PDF)

TY  - CONF
AU  - Jingwen Xin
PY  - 2022
DA  - 2022/04/29
TI  - Analysis on Financial Conditions of Listed Pharmaceutical Manufacturing Companies Based on F-score Model in the Context of COVID-19
BT  - Proceedings of the 2022 7th International Conference on Social Sciences and Economic Development (ICSSED 2022)
PB  - Atlantis Press
SP  - 529
EP  - 533
SN  - 2352-5428
UR  - https://doi.org/10.2991/aebmr.k.220405.087
DO  - 10.2991/aebmr.k.220405.087
ID  - Xin2022
ER  -